Zepbound and the Second Hormone
For roughly forty years, obesity medicine had almost nothing that worked well. Then it had one hormone. Now it has two — in a single molecule, injected once a week. Zepbound is the drug that made "20% of body weight" a realistic conversation in a clinic rather than a claim in an advertisement. Here's what it actually is, what the trial data shows, what it costs you in side effects, and why the second hormone turned out to matter so much.
What Zepbound actually is
Zepbound is Eli Lilly's brand name for tirzepatide, a once-weekly injection approved by the FDA in November 2023 for chronic weight management in adults. It is prescribed alongside a reduced-calorie diet and increased physical activity — not as a replacement for either.
Eligibility under the label is defined by body mass index: a BMI of 30 or above, or a BMI of 27 or above in the presence of at least one weight-related condition such as high blood pressure, abnormal cholesterol, type 2 diabetes, obstructive sleep apnea or cardiovascular disease.
It is given subcutaneously into the abdomen, thigh or upper arm, at any time of day, with or without food.
Zepbound and Mounjaro are the same molecule
This trips up almost everyone, so it is worth being blunt about it: Zepbound and Mounjaro both contain tirzepatide. Same active ingredient, same manufacturer, same weekly injection.
What differs is the label. Mounjaro was approved in 2022 for improving blood sugar control in adults with type 2 diabetes. Zepbound was approved in 2023 for weight management, and later for obstructive sleep apnea. Two brands, two sets of approved indications, two insurance pathways — one molecule underneath.
That separation is a regulatory and commercial decision rather than a pharmacological one. It matters practically, because which brand a person is prescribed affects coverage, documentation and sometimes availability.
The second hormone, and why it changed the numbers
Every widely used weight-loss injection before tirzepatide worked through one incretin hormone: GLP-1 (glucagon-like peptide-1). Tirzepatide adds a second: GIP (glucose-dependent insulinotropic polypeptide). One molecule, two receptors.
Both hormones are made in your gut after you eat. Both signal the pancreas to release insulin when glucose is high. And critically, receptors for both sit in the regions of the brain that regulate appetite.
The interesting part is that tirzepatide is not an even split. Pharmacology studies describe it as imbalanced and biased — it engages the GIP receptor more strongly than the GLP-1 receptor, and at the GLP-1 receptor it favours one internal signalling route over another, while pulling the receptor inside the cell less readily than natural GLP-1 does. Those are not incidental design details. They appear to be a meaningful part of why the drug performs the way it does.
Downstream, several things happen at once:
- In the brain. Labelled tirzepatide reaches the median eminence and area postrema — regions accessible to hormones circulating in the blood. It suppresses the activity of hunger-driving AgRP neurons, and dual GIP/GLP-1 activation suppresses them more powerfully than either signal alone.
- In fat tissue. Brown adipose tissue shifts toward energy-burning programmes, and pro-inflammatory immune cell infiltration in fat decreases — both linked to improved insulin sensitivity.
- In the pancreas and liver. Insulin release improves, and glucagon — the hormone that tells the liver to release glucose — drops substantially across therapeutic doses.
One finding is particularly telling. When researchers examined how much of the insulin-sensitivity improvement could be explained by weight loss alone, weight accounted for only a modest fraction of it at higher doses. The rest appears to come from direct remodelling of fat tissue. The drug is doing more than simply making people eat less.
| GLP-1 alone | GIP + GLP-1 (tirzepatide) | |
|---|---|---|
| Receptors targeted | One | Two, from a single molecule |
| Appetite signalling | Suppresses hunger neurons | Suppresses them more strongly; requires GIP-receptor neurons for the added effect |
| Fat tissue | Largely indirect, via weight loss | Direct remodelling alongside weight loss |
| Average weight change at 72 weeks | 13.7% (semaglutide, head-to-head) | 20.2% (tirzepatide, head-to-head) |
| GI side effects | Common, dose-escalation heavy | Common, dose-escalation heavy |
What the trials actually showed
SURMOUNT-1 was the pivotal obesity trial: 2,539 adults with obesity, or overweight plus a weight-related condition, and no diabetes. Over 72 weeks, average weight reductions were 15.0% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg, against 3.1% for placebo. At the top dose, 63% of participants lost at least 20% of their body weight, compared with 1.3% on placebo. Waist circumference fell by nearly 20 cm.
Participants with pre-diabetes continued for a further two years. At 176 weeks, the risk of progressing to type 2 diabetes was 94% lower than placebo. After a 17-week off-treatment follow-up, some weight returned — but the reduction in diabetes risk still held at 88%.
SURMOUNT-5 is the trial most people are really asking about: the first head-to-head comparison against Wegovy. Lilly randomised 751 adults with obesity and no diabetes to the maximum tolerated dose of tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg) for 72 weeks.
Tirzepatide produced an average 20.2% weight reduction against 13.7% for semaglutide — roughly 47% more relative weight loss, or 22.8 kg versus 15.0 kg. Waist circumference fell 20 cm versus 15 cm. Notably, discontinuation due to gastrointestinal side effects was lower in the tirzepatide group (2.7%) than the semaglutide group (5.6%), which cuts against the intuition that a stronger drug must be harder to tolerate.
One caveat worth stating plainly: SURMOUNT-5 was open-label and funded by the manufacturer of the winning drug. The result has been widely accepted, and the mechanism gives it a plausible explanation, but those are real limitations rather than footnotes.
The numbers that matter
- 20.9% average weight reduction at 15 mg over 72 weeks in SURMOUNT-1
- 20.2% vs 13.7% against semaglutide in the head-to-head SURMOUNT-5 trial
- 94% reduction in progression to type 2 diabetes at three years in participants with pre-diabetes
- 14% average weight regain within a year of stopping
The sleep apnea approval nobody expected
In December 2024, Zepbound became the first medication ever approved for obstructive sleep apnea — a condition previously treated with machines, mouthpieces and surgery, but never a drug.
The approval covers adults with a BMI of 30 or above who have moderate-to-severe OSA, defined as an apnea-hypopnea index of 15 or more events per hour.
SURMOUNT-OSA tested it across two parallel groups: people unable or unwilling to use positive airway pressure therapy, and people already on PAP who planned to stay on it. In both, tirzepatide significantly reduced the apnea-hypopnea index compared with placebo, alongside reductions in body weight, hypoxic burden, inflammatory markers and systolic blood pressure.
An important clarification, because it gets misreported: this is not a replacement for CPAP. The clinical framing positions it as part of comprehensive OSA care alongside PAP therapy, oral appliances or surgery where appropriate. No head-to-head trial has compared it against other OSA treatments, and most insurers require first-line therapies to be tried first.
Why the dose climbs slowly
Zepbound comes in six strengths: 2.5, 5, 7.5, 10, 12.5 and 15 mg, each in a 0.5 mL dose. Treatment is structured as a ladder — starting at 2.5 mg weekly for four weeks, then stepping up in 2.5 mg increments at four-week intervals, to a maximum of 15 mg weekly.
The 2.5 mg starting dose is not a treatment dose. It exists purely to let the gut adapt. Nausea, vomiting and diarrhoea cluster heavily around dose increases, and the slow ladder is the main tool for keeping them manageable.
This is also where most self-directed use goes wrong. The escalation schedule exists because it was tested, and because someone is monitoring what happens at each step. Compressing it, or guessing at it, converts a predictable side-effect profile into an unpredictable one.
Side effects and safety
The most common adverse events reported in 5% or more of trial participants were nausea, diarrhoea, vomiting, constipation, abdominal pain, indigestion, injection-site reactions, fatigue, hypersensitivity reactions, burping, hair loss and acid reflux. Most gastrointestinal effects appeared during dose escalation and eased over time — but they were more common than with placebo, and more people stopped treatment because of them.
Zepbound carries a boxed warning for thyroid C-cell tumours. In a two-year rat study, tirzepatide caused a dose-dependent and duration-dependent increase in thyroid C-cell tumours at clinically relevant exposures. Whether this translates to humans is unknown, and no confirmed human cases have been attributed to the drug in clinical trials — but the warning stands, and it drives a hard contraindication.
Zepbound is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma, anyone with Multiple Endocrine Neoplasia syndrome type 2, and anyone with known serious hypersensitivity to tirzepatide or its excipients. Routine calcitonin testing and thyroid ultrasound are considered of uncertain value for monitoring, so the practical guidance is symptom-based: report any new neck lump or swelling, persistent hoarseness, difficulty swallowing or shortness of breath.
Other labelled concerns include severe gastrointestinal disease, acute gallbladder disease, pancreatitis, and serious hypersensitivity reactions including anaphylaxis and angioedema. The drug was not studied in people with a history of pancreatitis or severe gastroparesis. It should not be combined with other tirzepatide-containing products or with any GLP-1 receptor agonist.
Common thyroid conditions do not disqualify anyone. Hashimoto's, Graves' disease, hypothyroidism managed with levothyroxine, benign nodules, and thyroid surgery for non-medullary reasons all sit outside the contraindication, which is specific to medullary thyroid carcinoma and MEN 2.
What happens when you stop
This is the part of the Zepbound story that gets the least attention and deserves the most.
SURMOUNT-4 was built specifically to answer it. Participants took tirzepatide openly for 36 weeks, losing an average of 20.9% of their body weight. They were then randomly assigned either to continue the drug or to switch to placebo for another 52 weeks.
Those who continued lost a further 5.5%. Those who stopped regained 14% — a gap of roughly 19 percentage points between the two groups. By week 88, 89.5% of the continuing group had held on to at least 80% of their original weight loss. In the placebo group, 16.6% had.
A later analysis of the same trial followed what happened to health markers, not just the scale. Among those who stopped, 82% regained more than a quarter of what they had lost — and the improvements in waist circumference, blood pressure, cholesterol, blood glucose and insulin resistance reversed in proportion to the weight that came back.
The conclusion drawn by the investigators was direct: obesity behaves like a chronic condition, and this is maintenance therapy rather than a course of treatment with an endpoint. People frequently assume they can stop once they hit a goal weight. The data says otherwise.
The access picture in 2026
The regulatory ground under this drug has shifted repeatedly, and where things stand now is different from where they stood even a year ago.
During the 2022–2024 shortages, compounding pharmacies were legally permitted to produce copies of tirzepatide. That window has closed. The FDA declared the tirzepatide shortage resolved in late 2024, and semaglutide followed in February 2025. Enforcement discretion for smaller compounding pharmacies ended in February 2025. In April 2026, the FDA proposed permanently excluding semaglutide, tirzepatide and liraglutide from the list of bulk substances that large-scale outsourcing facilities may use — a step that, if finalised, would close the last significant legal route for most compounded versions. Dozens of warning letters have gone out to companies over misleading claims.
Quality has been a live concern alongside the legal question. Many compounders added extra ingredients — vitamin B12 most often, but also B6, niacinamide, glycine and carnitine — marketed as personalisation, none with evidence supporting a weight-loss benefit. Testing published in 2026 found that tirzepatide and B12 can chemically react to form a new impurity not present in the approved product, detected across every sampled batch in one manufacturer's analysis.
On the other side, genuine generics are moving. Applications for generic tirzepatide were accepted for FDA review in mid-2026. That is the beginning of a regulatory process, not an imminent launch — Lilly's US patents run to 2036 — and nothing currently sold as "generic tirzepatide" is one.
Where research compounds fit — and where they don't
Tirzepatide as a molecule is also studied outside the branded pharmaceutical context. That is a legitimate area of research interest, and it is worth being precise about what it is and is not.
A research-grade compound is characterised material supplied for laboratory work. It is not a prescription medicine. It does not come with the label, the titration schedule, the pharmacist, the prescriber, the monitoring, the manufacturing controls or the adverse-event reporting system that make branded Zepbound what it is. Those things are not packaging — they are a substantial part of the safety profile described above.
If you are researching this class of compounds, the same principle applies here as anywhere: independent verification of identity and purity is the baseline, not an extra. Our COA database holds third-party testing for everything in our catalogue, including tirzepatide, semaglutide and the next-generation triple agonist retatrutide.
If you are a person considering treatment for obesity or sleep apnea, the honest answer is that this belongs with a licensed clinician who can assess your history, manage the dose ladder and monitor what happens.
Explore the metabolic research category
Browse our research-grade metabolic and incretin compounds, each supplied with third-party laboratory testing and handled under controlled cold-chain conditions.
View metabolic peptidesFrequently asked questions
Is Zepbound the same as Mounjaro?
The active ingredient is identical — both are tirzepatide from Eli Lilly. The difference is the approved indication. Mounjaro is licensed for blood sugar control in type 2 diabetes; Zepbound is licensed for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity.
How is Zepbound different from Wegovy?
Wegovy contains semaglutide, which acts on one receptor (GLP-1). Zepbound contains tirzepatide, which acts on two (GIP and GLP-1). In the head-to-head SURMOUNT-5 trial, tirzepatide produced 20.2% average weight loss at 72 weeks versus 13.7% for semaglutide.
What happens if I stop taking it?
Most people regain a substantial share of what they lost. In SURMOUNT-4, participants who switched to placebo after 36 weeks regained an average of 14% over the following year, while those who continued lost an additional 5.5%. Improvements in blood pressure, cholesterol and blood sugar reversed in proportion to the weight regained.
Why does the dose start so low?
The 2.5 mg starting dose is a tolerance step, not a treatment dose. Gastrointestinal side effects concentrate around dose increases, so the four-week ladder gives the digestive system time to adapt before each step up. The maximum is 15 mg weekly.
Who should not take Zepbound?
Anyone with a personal or family history of medullary thyroid carcinoma, anyone with Multiple Endocrine Neoplasia syndrome type 2, and anyone with a known serious hypersensitivity to tirzepatide or its ingredients. It also has not been studied in people with a history of pancreatitis or severe gastroparesis, and should not be combined with other tirzepatide products or any GLP-1 receptor agonist.
Can Zepbound replace a CPAP machine?
No. The sleep apnea approval positions it as part of comprehensive care alongside PAP therapy, oral appliances or surgery — not as a substitute. There is no head-to-head evidence comparing it with other OSA treatments.
The bottom line
Zepbound earned its reputation. Adding a second incretin receptor to a single molecule produced results that a decade of single-hormone drugs had not, and it did so while being no harder to tolerate in a direct comparison — arguably easier.
What it did not do is make obesity a solvable problem with a finish line. The withdrawal data is unambiguous: the benefit lasts as long as the treatment does. That reframes the decision from "how much can I lose" to "is this something I can sustain, medically and financially, for years." Which is a harder question, and a more honest one.
For more on how these compounds compare, our Info Center covers each one individually, and the metabolic category groups them by research application.
Zepbound® and Mounjaro® are registered trademarks of Eli Lilly and Company. Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S. Peptides Costa Rica is not affiliated with, endorsed by, or sponsored by either company, and does not sell these branded products. This article is provided for educational and informational purposes only. It is not medical advice, and it is not intended to diagnose, treat, cure or prevent any condition. Tirzepatide is a prescription medicine and should only be used under the supervision of a licensed healthcare professional. Products offered by Peptides Costa Rica are intended strictly for laboratory research use only. They are not approved or licensed by the FDA for the prevention, diagnosis, treatment or cure of any disease. Not for human or veterinary use.
